Who is sponsoring NCT04836559?

NCT04836559 is sponsored by Janssen Research & Development, LLC.

What condition does NCT04836559 study?

NCT04836559 studies Focal Onset Seizures.

What drugs are being tested in NCT04836559?

Interventions: JNJ-40411813, Placebo.

What is the status of NCT04836559?

NCT04836559 is currently COMPLETED.

Last reviewed 2025-07-03 · How we verify

A Study to Investigate JNJ-40411813 in Combination With Levetiracetam or Brivaracetam in Epilepsy

NCT04836559 PHASE2 COMPLETED Results posted

The purpose of this study is to evaluate the efficacy of up to 3 dose levels of adjunctive JNJ-40411813 compared to placebo based on the time to baseline monthly seizure count in participants with focal onset seizures who are receiving levetiracetam or brivaracetam and up to 3 other anti-epileptic drugs (AEDs) (double-blind treatment period) and to evaluate the long-term efficacy and safety of adjunctive therapy with JNJ-40411813 in participants with epilepsy (open-label extension \[OLE\] period).

Details

Lead sponsor	Janssen Research & Development, LLC
Phase	PHASE2
Status	COMPLETED
Enrolment	110
Start date	Tue May 18 2021 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Thu Feb 08 2024 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

Focal Onset Seizures

Interventions

JNJ-40411813
Placebo

Countries

Russia, Ukraine, Belgium, Germany, Poland, South Korea, United States, Spain